Lexeo CFO receives 54,750 stock options

Lexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposal of Assets. At the effective time of the Merger (the “ Effective Time ”), each outstanding share of Mantle capital stock (other than shares held by Mantle as treasury shares, shares held by Lexeo or Merger Sub, and Dissenting Shares)

Leerink Partners kept an Outperform rating and $15 price target on Lexeo Therapeutics, implying 268.6% upside from its Sep 22 close. The firm cited strong clinical data for LX2006, targeting Friedreich ataxia cardiomyopathy, and strategic collaborations to address gene therapy challenges.

Lexeo Therapeutics (LXEO) is acquiring Mantle Therapeutics for up to $21.3M to expand its Friedreich ataxia pipeline, adding new therapeutic candidates. The deal includes an $8.3M upfront payment and potential milestone payments. Lexeo also announced new research collaborations. LXEO stock is up 3.90% at $4.23.

Lexeo Therapeutics (LXEO) stock rose 4.2% pre-market after announcing strategic transactions, including the acquisition of Mantle Therapeutics for up to $21.3M. The deal adds four FA programs to its pipeline, with LX3010 showing early positive data. Lexeo also entered three research collaborations and maintained its cash runway guidance. Raymond James reiterated a Strong Buy rating and $24.00 price target.

Lexeo Therapeutics (NASDAQ:LXEO) shares rose 5.4% premarket after announcing a deal to acquire Mantle Therapeutics for up to $21.3M, expanding its Friedreich ataxia treatment platform. The acquisition includes four therapeutic programs, with $8.3M upfront payment and $13M in potential milestones. Lexeo also launched three research collaborations and expects to submit an IND in 2027. Raymond James reiterated a Strong Buy rating and $24.00 price target.

Lexeo Therapeutics (LXEO) reported Q2 2026 results and updates. It initiated the SUNRISE-FA 2 pivotal trial for LX2006 in June 2026, with first site activated and first patient enrolled. FDA granted RMAT designation for LX2020. Q2 R&D was $19.0M, net loss $25.9M ($0.30/share). Cash was $234.2M. Topline LX2006 data expected 2H 2027.